TY - JOUR
T1 - The role of small airway dysfunction in asthma control and exacerbations
T2 - a longitudinal, observational analysis using data from the ATLANTIS study
AU - ATLANTIS study group
AU - Kraft, Monica
AU - Richardson, Matthew
AU - Hallmark, Brian
AU - Billheimer, Dean
AU - Van den Berge, Maarten
AU - Fabbri, Leonardo M.
AU - Van der Molen, Thys
AU - Nicolini, Gabriele
AU - Papi, Alberto
AU - Rabe, Klaus F.
AU - Singh, Dave
AU - Brightling, Chris
AU - Siddiqui, Salman
AU - Pizzichini, Emilio
AU - Cukier, Alberto
AU - Stelmach, Rafael
AU - Olivenstein, Ronald
AU - Zhang, Qingling
AU - Badorrek, Philipp
AU - Gessner, Christian
AU - Scichilone, Nicola
AU - Chetta, Alfredo
AU - Paggiaro, Pierluigi
AU - Milleri, Stefano
AU - D'Amato, Mariella
AU - Spanevello, Antonio
AU - Foschino, Maria Pia
AU - Boersma, Willem Germen
AU - Broeders, Marielle
AU - Vroegop, J. Sebastiaan
AU - Plaza Moral, Vicente
AU - Djukanovic, Ratko
AU - Usmani, Omar
AU - Schilz, Robert
AU - Martin, Richard
AU - Hanania, Nicola
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/7
Y1 - 2022/7
N2 - Background: Although small airway disease is a feature of asthma, its association with relevant asthma outcomes remains unclear. The ATLANTIS study was designed to identify the combination of physiological and imaging variables that best measure the presence and extent of small airway disease in asthma, both cross-sectionally and longitudinally. In this longitudinal analysis, we evaluated which small airway parameters studied were most strongly associated with asthma control, exacerbations, and quality of life. Methods: In this observational cohort study, participants with mild, moderate, or severe stable asthma were recruited between June 30, 2014, and March 3, 2017, via medical databases and advertisements in nine countries worldwide. Eligible participants were aged 18–65 years with a clinical asthma diagnosis for at least 6 months. Participants were followed up for 1 year, with visits at baseline, 6 months, and 12 months. Physiological tests included spirometry, lung volumes, impulse oscillometry, multiple breath nitrogen washout (MBNW), and percentage decrease in forced vital capacity during methacholine challenge. CT densitometry was performed to evaluate small airway disease. We examined the associations between these measurements and asthma exacerbations, asthma control, and quality of life using univariate and multivariate analyses. A composite ordinal score comprising percent predicted R5–20 (resistance of small-to-mid-sized airways), AX (area of reactance), and X5 (reactance of more central, conducting small airways at 5 Hz) was constructed. Findings: 773 participants (median age 46 years [IQR 34–54]; 450 [58%] female) were included in this longitudinal study. Univariate analyses showed that components of impulse oscillometry, lung volumes, MBNW, and forced expiratory flow at 25–75% of FVC were significantly correlated with asthma control and exacerbations (Spearman correlations 0·20–0·25, p<0·0001 after Bonferroni correction). As a composite of impulse oscillometry, the ordinal score independently predicted asthma control and exacerbations in a multivariate analysis with known exacerbation predictors. CT parameters were not significantly correlated with asthma control, exacerbation, or quality of life. Interpretation: Small airway disease, as measured by physiological tests, is longitudinally associated with clinically important asthma outcomes, such as asthma control and exacerbations. Funding: Chiesi Farmaceutici.
AB - Background: Although small airway disease is a feature of asthma, its association with relevant asthma outcomes remains unclear. The ATLANTIS study was designed to identify the combination of physiological and imaging variables that best measure the presence and extent of small airway disease in asthma, both cross-sectionally and longitudinally. In this longitudinal analysis, we evaluated which small airway parameters studied were most strongly associated with asthma control, exacerbations, and quality of life. Methods: In this observational cohort study, participants with mild, moderate, or severe stable asthma were recruited between June 30, 2014, and March 3, 2017, via medical databases and advertisements in nine countries worldwide. Eligible participants were aged 18–65 years with a clinical asthma diagnosis for at least 6 months. Participants were followed up for 1 year, with visits at baseline, 6 months, and 12 months. Physiological tests included spirometry, lung volumes, impulse oscillometry, multiple breath nitrogen washout (MBNW), and percentage decrease in forced vital capacity during methacholine challenge. CT densitometry was performed to evaluate small airway disease. We examined the associations between these measurements and asthma exacerbations, asthma control, and quality of life using univariate and multivariate analyses. A composite ordinal score comprising percent predicted R5–20 (resistance of small-to-mid-sized airways), AX (area of reactance), and X5 (reactance of more central, conducting small airways at 5 Hz) was constructed. Findings: 773 participants (median age 46 years [IQR 34–54]; 450 [58%] female) were included in this longitudinal study. Univariate analyses showed that components of impulse oscillometry, lung volumes, MBNW, and forced expiratory flow at 25–75% of FVC were significantly correlated with asthma control and exacerbations (Spearman correlations 0·20–0·25, p<0·0001 after Bonferroni correction). As a composite of impulse oscillometry, the ordinal score independently predicted asthma control and exacerbations in a multivariate analysis with known exacerbation predictors. CT parameters were not significantly correlated with asthma control, exacerbation, or quality of life. Interpretation: Small airway disease, as measured by physiological tests, is longitudinally associated with clinically important asthma outcomes, such as asthma control and exacerbations. Funding: Chiesi Farmaceutici.
UR - http://www.scopus.com/inward/record.url?scp=85134022335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134022335&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(21)00536-1
DO - 10.1016/S2213-2600(21)00536-1
M3 - Article
C2 - 35247313
AN - SCOPUS:85134022335
SN - 2213-2600
VL - 10
SP - 661
EP - 668
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 7
ER -